Oncologie
Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study
Lire la suite